Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Shares Outstanding (Weighted Average): 2010-2024

Historic Shares Outstanding (Weighted Average) for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $71.1 million.

  • Altimmune's Shares Outstanding (Weighted Average) rose 24.18% to $88.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.3 million, marking a year-over-year increase of 24.18%. This contributed to the annual value of $71.1 million for FY2024, which is 32.38% up from last year.
  • According to the latest figures from FY2024, Altimmune's Shares Outstanding (Weighted Average) is $71.1 million, which was up 32.38% from $53.7 million recorded in FY2023.
  • Over the past 5 years, Altimmune's Shares Outstanding (Weighted Average) peaked at $71.1 million during FY2024, and registered a low of $33.1 million during FY2020.
  • For the 3-year period, Altimmune's Shares Outstanding (Weighted Average) averaged around $58.0 million, with its median value being $53.7 million (2023).
  • Data for Altimmune's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 115.61% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Altimmune's Shares Outstanding (Weighted Average) stood at $33.1 million in 2020, then spiked by 30.70% to $43.2 million in 2021, then increased by 13.73% to $49.2 million in 2022, then climbed by 9.30% to $53.7 million in 2023, then spiked by 32.38% to $71.1 million in 2024.